Measuring school level attributable risk to support school-based HPV vaccination programs
Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics...
Saved in:
Published in | BMC public health Vol. 22; no. 1; pp. 822 - 10 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
25.04.2022
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1471-2458 1471-2458 |
DOI | 10.1186/s12889-022-13088-x |
Cover
Abstract | Background
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.
Methods
A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).
Results
The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46).
Conclusion
This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. |
---|---|
AbstractList | In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.
A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).
The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46).
This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46). This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Keywords: HPV vaccines, Primary prevention, Cervical cancer, Immunisation programs, School-based, Health equity In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.BACKGROUNDIn Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).METHODSA population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46).RESULTSThe factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46).This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.CONCLUSIONThis analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Abstract Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. |
ArticleNumber | 822 |
Audience | Academic |
Author | Leask, J. Venn, A. Selvey, L. Veitch, M. Guy, R. Sanci, L. Sisnowski, J. Kaldor, J. Kang, M. Sheppeard, V. Lane, N. Vujovich-Dunn, C. Lorch, R. Canfell, K. Kidd, M. Davies, C. Gidding, H. Effler, P. Whop, L. Meijer, D. Burns, S. Smith, M. Brotherton, J. M. L. Ennis, S. Hocking, J. Wand, H. Skinner, S. R. Thomson, C. Temple-Smith, M. |
Author_xml | – sequence: 1 givenname: C. surname: Vujovich-Dunn fullname: Vujovich-Dunn, C. email: cvujovich-dunn@kirby.unsw.edu.au organization: University of New South Wales, Kirby Institute – sequence: 2 givenname: H. surname: Wand fullname: Wand, H. organization: University of New South Wales, Kirby Institute – sequence: 3 givenname: J. M. L. surname: Brotherton fullname: Brotherton, J. M. L. organization: Australian Centre for the Prevention of Cervical Cancer, Population Health, University of Melbourne, Melbourne School of Population and Global Health – sequence: 4 givenname: H. surname: Gidding fullname: Gidding, H. organization: University of Sydney, Northern Clinical School, Women and Babies Research, Kolling Institute, Northern Sydney Local Health District, School of Population Health, University of New South Wales, National Centre for Immunisation Research and Surveillance – sequence: 5 givenname: J. surname: Sisnowski fullname: Sisnowski, J. organization: University of New South Wales, Kirby Institute, Australian National University, National Centre for Epidemiology & Population Health – sequence: 6 givenname: R. surname: Lorch fullname: Lorch, R. organization: University of New South Wales, Kirby Institute – sequence: 7 givenname: M. surname: Veitch fullname: Veitch, M. organization: Department of Health and Human Services, Tasmanian Government – sequence: 8 givenname: V. surname: Sheppeard fullname: Sheppeard, V. organization: Communicable Diseases Branch, NSW Health, University of Sydney, Sydney School of Public Health – sequence: 9 givenname: P. surname: Effler fullname: Effler, P. organization: Communicable Disease Control Directorate, Department of Health – sequence: 10 givenname: S. R. surname: Skinner fullname: Skinner, S. R. organization: University of Sydney, Specialty of Child and Adolescent Health, Faculty of Medicine and Health, Children’s Hospital Westmead, Sydney Children’s Hospitals Network – sequence: 11 givenname: A. surname: Venn fullname: Venn, A. organization: Menzies Institute for Medical Research, University of Tasmania – sequence: 12 givenname: C. surname: Davies fullname: Davies, C. organization: University of Sydney, Specialty of Child and Adolescent Health, Faculty of Medicine and Health, Children’s Hospital Westmead, Sydney Children’s Hospitals Network – sequence: 13 givenname: J. surname: Hocking fullname: Hocking, J. organization: University of Melbourne, Melbourne School of Population and Global Health – sequence: 14 givenname: L. surname: Whop fullname: Whop, L. organization: Australian National University, National Centre for Epidemiology & Population Health, Menzies School of Health Research, Charles Darwin University – sequence: 15 givenname: J. surname: Leask fullname: Leask, J. organization: National Centre for Immunisation Research and Surveillance, University of Sydney, Sydney Nursing School, Faculty of Medicine and Health – sequence: 16 givenname: K. surname: Canfell fullname: Canfell, K. organization: The Daffodil Centre, University of Sydney, A Joint Venture With Cancer Council NSW – sequence: 17 givenname: L. surname: Sanci fullname: Sanci, L. organization: University of Melbourne, Medicine, Dentistry and Health Sciences – sequence: 18 givenname: M. surname: Smith fullname: Smith, M. organization: The Daffodil Centre, University of Sydney, A Joint Venture With Cancer Council NSW, School of Public Health, University of Sydney – sequence: 19 givenname: M. surname: Kang fullname: Kang, M. organization: University of Sydney, Westmead Clinical School – sequence: 20 givenname: M. surname: Temple-Smith fullname: Temple-Smith, M. organization: University of Melbourne, Medicine, Dentistry and Health Sciences – sequence: 21 givenname: M. surname: Kidd fullname: Kidd, M. organization: Flinders University, Southgate Institute for Health, Society and Equity – sequence: 22 givenname: S. surname: Burns fullname: Burns, S. organization: Curtin University, School of Population Health – sequence: 23 givenname: L. surname: Selvey fullname: Selvey, L. organization: University of Queensland, School of Public Health – sequence: 24 givenname: D. surname: Meijer fullname: Meijer, D. organization: Immunisation Unit, Health Protection NSW, St Leonard’s – sequence: 25 givenname: S. surname: Ennis fullname: Ennis, S. organization: Immunisation Unit, Health Protection NSW, St Leonard’s – sequence: 26 givenname: C. surname: Thomson fullname: Thomson, C. organization: Communicable Disease Control Directorate, Department of Health – sequence: 27 givenname: N. surname: Lane fullname: Lane, N. organization: Department of Health and Human Services, Tasmanian Government – sequence: 28 givenname: J. surname: Kaldor fullname: Kaldor, J. organization: University of New South Wales, Kirby Institute – sequence: 29 givenname: R. surname: Guy fullname: Guy, R. organization: University of New South Wales, Kirby Institute |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35468743$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAUhSNURB_wB1igSGzYpPgV29kgVVWhlYpgAUisLNu5ST1k4mA7o_Lv8TxKOxWqvbBln_NZ9_ocFwejH6EoXmN0irHk7yMmUjYVIqTCFElZ3T4rjjATuCKslgcP9ofFcYwLhLCQNXlRHNKacSkYPSp-fgYd5-DGvoz2xvuhHGAFQ6lTCs7MSZsByuDirzL5Ms7T5EPaKSujI7Tl5dcf5Upb60adnB_LKfg-6GV8WTzv9BDh1W49Kb5_vPh2flldf_l0dX52XVmORKpACMGRlQ1GEhgWuBGGc9w2wEEzySi0lujWUEEYNcxwgmoragK1BYOajp4UV1tu6_VCTcEtdfijvHZqc-BDr3RIzg6gWNtyrSnqmow2tTG4bVtBRAcUCIcmsz5sWdNslvlhGFPQwx50_2Z0N6r3K9UgynM_M-DdDhD87xliUksXLQyDHsHPURFe1zVHXPAsfftIuvBzGHOrsmo9BG-ae1WvcwFu7Hx-166h6kwgzHHDpMyq0_-o8mxh6WxOTefy-Z7hzcNC_1V4F4wskFuBDT7GAJ2yLm0-OJPdoDBS6wyqbQZVzqDaZFDdZit5ZL2jP2miW1Oc1mGEcN-NJ1x_AYvx7z0 |
CitedBy_id | crossref_primary_10_1080_14681811_2022_2084373 crossref_primary_10_3390_vaccines12080922 crossref_primary_10_1111_josh_70003 crossref_primary_10_3390_vaccines12080888 crossref_primary_10_1016_j_vaccine_2024_07_048 crossref_primary_10_1016_j_ypmed_2023_107542 crossref_primary_10_1186_s12889_024_19322_y crossref_primary_10_4103_ijmr_ijmr_1052_23 crossref_primary_10_3390_pathogens12121380 crossref_primary_10_3389_fimmu_2023_1150238 crossref_primary_10_1016_j_mcna_2023_05_012 |
Cites_doi | 10.1080/21645515.2019.1640556 10.1016/S0140-6736(11)60551-5 10.3390/vaccines9070687 10.1136/sti.2009.040188 10.1093/ije/29.5.813 10.1136/bmjopen-2014-006422 10.1071/SH09140 10.1016/j.vaccine.2016.01.061 10.1111/1753-6405.12218 10.4103/2229-5070.175024 10.1542/peds.101.6.970 10.3109/13668250.2017.1310827 10.1111/jpc.12030 10.1136/bmj.39541.534109.BE 10.1016/j.vaccine.2014.01.081 10.1016/S0140-6736(19)30298-3 10.1093/pubmed/fdaa164 10.1002/ijc.30716 10.1016/j.ejca.2017.05.026 10.18590/mjm.2017.vol3.iss2.8 10.1056/NEJMoa1917338 10.1016/S2468-2667(16)30001-9 10.1016/j.vaccine.2021.08.076 10.1016/j.vaccine.2010.04.038 10.1136/bmjopen-2019-029087 10.1016/S2214-109X(19)30482-6 10.1016/S0140-6736(20)30068-4 10.5694/mja11.11360 10.1016/j.vaccine.2018.11.034 10.1007/978-1-4020-5614-7_2685 10.1080/14760584.2018.1548282 10.1200/JGO.2016.008151 10.1016/S2214-109X(16)30099-7 10.1017/S095026881000066X 10.1186/s12889-016-3195-6 10.1136/jech-2013-202629 10.3390/ijerph17217997 10.5694/mja2.50221 10.1136/bmj.f2032 10.1111/1753-6405.12149 10.1371/journal.pmed.1000270 10.3109/13625180903229605 10.1002/cncr.29954 10.1093/pubmed/fdt042 10.5694/mja16.00597 10.1186/1741-7015-11-227 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10.1016/S1470-2045(12)70137-7 10.3111/13696998.2013.793691 10.1136/jech-2013-202620 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T2 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 5PM DOA |
DOI | 10.1186/s12889-022-13088-x |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Technology Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection (subscription) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Technology Collection (via ProQuest SciTech Premium Collection) ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection Health & Medical Collection (Alumni) Medical Database ProQuest Engineering Database Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1471-2458 |
EndPage | 10 |
ExternalDocumentID | oai_doaj_org_article_4dd6aa30f9ea4b5bb1ddd727fe3e26e9 PMC9036743 A701619488 35468743 10_1186_s12889_022_13088_x |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Australia United Kingdom Canada United States--US Western Australia Australia New South Wales Australia Tasmania Australia |
GeographicLocations_xml | – name: Australia – name: United Kingdom – name: Tasmania Australia – name: Canada – name: New South Wales Australia – name: United States--US – name: Western Australia Australia |
GroupedDBID | --- 0R~ 23N 2WC 2XV 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ITC KQ8 L6V M1P M48 M7S M~E O5R O5S OK1 OVT P2P PATMY PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T2 7XB 8FK AZQEC C1K DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c607t-e77760c89108e417197b661d9e6ea4843edc2adb37243b4b6205c752e5ceb09f3 |
IEDL.DBID | BENPR |
ISSN | 1471-2458 |
IngestDate | Wed Aug 27 01:31:26 EDT 2025 Thu Aug 21 14:19:54 EDT 2025 Mon Sep 08 14:27:51 EDT 2025 Fri Jul 25 18:59:23 EDT 2025 Tue Jun 17 21:27:21 EDT 2025 Tue Jun 10 20:10:56 EDT 2025 Wed Feb 19 02:25:59 EST 2025 Thu Apr 24 22:59:30 EDT 2025 Tue Jul 01 00:56:31 EDT 2025 Sat Sep 06 07:29:12 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Health equity HPV vaccines Primary prevention Immunisation programs School-based Cervical cancer |
Language | English |
License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c607t-e77760c89108e417197b661d9e6ea4843edc2adb37243b4b6205c752e5ceb09f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2666667699?pq-origsite=%requestingapplication%&accountid=15518 |
PMID | 35468743 |
PQID | 2666667699 |
PQPubID | 44782 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_4dd6aa30f9ea4b5bb1ddd727fe3e26e9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9036743 proquest_miscellaneous_2655560676 proquest_journals_2666667699 gale_infotracmisc_A701619488 gale_infotracacademiconefile_A701619488 pubmed_primary_35468743 crossref_citationtrail_10_1186_s12889_022_13088_x crossref_primary_10_1186_s12889_022_13088_x springer_journals_10_1186_s12889_022_13088_x |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-04-25 |
PublicationDateYYYYMMDD | 2022-04-25 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | BMC public health |
PublicationTitleAbbrev | BMC Public Health |
PublicationTitleAlternate | BMC Public Health |
PublicationYear | 2022 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | BPXZ Yawn (13088_CR41) 2000; 13 A Acampora (13088_CR60) 2020; 17 B Feiring (13088_CR36) 2015; 5 E Préaud (13088_CR6) 2013; 16 13088_CR19 M Arbyn (13088_CR18) 2018; 17 13088_CR16 H Ali (13088_CR10) 2013; 346 13088_CR59 ED O'Brien (13088_CR49) 2000; 29 13088_CR58 13088_CR57 PA Agius (13088_CR37) 2010; 28 J O'Neill (13088_CR52) 2020; 16 DB Mak (13088_CR29) 2013; 49 M Arbyn (13088_CR12) 2018; 5 J O'Neill (13088_CR54) 2019; 37 C de Martel (13088_CR3) 2017; 141 J O’Neill (13088_CR53) 2019; 44 PJ Smith (13088_CR42) 2016; 34 LJ Whop (13088_CR50) 2016; 122 L Bruni (13088_CR2) 2016; 4 AM Spencer (13088_CR34) 2014; 68 H Ali (13088_CR11) 2017; 206 H Wand (13088_CR46) 2016; 16 M Arbyn (13088_CR1) 2020; 8 M Drolet (13088_CR13) 2019; 394 13088_CR45 13088_CR44 SA Roberts (13088_CR32) 2011; 139 K Sinka (13088_CR35) 2014; 68 B Barbaro (13088_CR31) 2012; 196 A Ross (13088_CR40) 1998; 101 J Lei (13088_CR15) 2020; 383 AA Hussein (13088_CR5) 2017; 82 JM Brotherton (13088_CR48) 2019; 211 H Fisher (13088_CR33) 2014; 36 13088_CR39 JM Brotherton (13088_CR21) 2011; 377 G Ogilvie (13088_CR23) 2010; 7 DM Gertig (13088_CR14) 2013; 11 C de Martel (13088_CR4) 2012; 13 13088_CR43 M Gottvall (13088_CR17) 2009; 14 J Mandal (13088_CR55) 2016; 6 M Watson (13088_CR51) 2014; 38 L Brabin (13088_CR22) 2008; 336 M Brisson (13088_CR56) 2020; 395 JM Walboomers (13088_CR8) 1999; 189 13088_CR28 13088_CR27 HJ Larson (13088_CR38) 2014; 32 13088_CR26 13088_CR25 13088_CR24 M Brisson (13088_CR20) 2016; 1 B Barbaro (13088_CR30) 2014; 38 K Tiley (13088_CR47) 2019; 9 M Pirotta (13088_CR7) 2010; 86 S Arrossi (13088_CR9) 2017; 3 EJ Mavundza (13088_CR61) 2021; 9 |
References_xml | – volume: 16 start-page: 7 issue: 1 year: 2020 ident: 13088_CR52 publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2019.1640556 – volume: 377 start-page: 2085 issue: 9783 year: 2011 ident: 13088_CR21 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(11)60551-5 – volume: 9 start-page: 687 issue: 7 year: 2021 ident: 13088_CR61 publication-title: Vaccines (Basel) doi: 10.3390/vaccines9070687 – volume: 86 start-page: 181 issue: 3 year: 2010 ident: 13088_CR7 publication-title: Sex Trans Infect doi: 10.1136/sti.2009.040188 – volume: 29 start-page: 813 issue: 5 year: 2000 ident: 13088_CR49 publication-title: Int J Epidemiol doi: 10.1093/ije/29.5.813 – ident: 13088_CR57 – volume: 5 start-page: e006422 issue: 5 year: 2015 ident: 13088_CR36 publication-title: BMJ Open. doi: 10.1136/bmjopen-2014-006422 – ident: 13088_CR19 – ident: 13088_CR25 – ident: 13088_CR39 doi: 10.1071/SH09140 – volume: 34 start-page: 1604 issue: 13 year: 2016 ident: 13088_CR42 publication-title: Vaccine doi: 10.1016/j.vaccine.2016.01.061 – volume: 38 start-page: 419 issue: 5 year: 2014 ident: 13088_CR30 publication-title: Aust N Z J Public Health doi: 10.1111/1753-6405.12218 – ident: 13088_CR44 – volume: 6 start-page: 5 issue: 1 year: 2016 ident: 13088_CR55 publication-title: Trop Parasitol doi: 10.4103/2229-5070.175024 – volume: 101 start-page: 970 issue: 6 year: 1998 ident: 13088_CR40 publication-title: Pediatrics doi: 10.1542/peds.101.6.970 – volume: 44 start-page: 98 issue: 1 year: 2019 ident: 13088_CR53 publication-title: J Intellect Dev Disabil doi: 10.3109/13668250.2017.1310827 – volume: 49 start-page: 895 issue: 11 year: 2013 ident: 13088_CR29 publication-title: J Paediatr Child Health doi: 10.1111/jpc.12030 – volume: 336 start-page: 1056 issue: 7652 year: 2008 ident: 13088_CR22 publication-title: BMJ (Clinical research ed) doi: 10.1136/bmj.39541.534109.BE – volume: 32 start-page: 2150 issue: 19 year: 2014 ident: 13088_CR38 publication-title: Vaccine doi: 10.1016/j.vaccine.2014.01.081 – volume: 394 start-page: 497 issue: 10197 year: 2019 ident: 13088_CR13 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(19)30298-3 – ident: 13088_CR59 doi: 10.1093/pubmed/fdaa164 – volume: 141 start-page: 664 issue: 4 year: 2017 ident: 13088_CR3 publication-title: Int J Cancer doi: 10.1002/ijc.30716 – ident: 13088_CR45 – volume: 82 start-page: 115 year: 2017 ident: 13088_CR5 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.05.026 – ident: 13088_CR24 – ident: 13088_CR58 doi: 10.18590/mjm.2017.vol3.iss2.8 – volume: 383 start-page: 1340 issue: 14 year: 2020 ident: 13088_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1917338 – volume: 1 start-page: e8 issue: 1 year: 2016 ident: 13088_CR20 publication-title: Lancet Public Health doi: 10.1016/S2468-2667(16)30001-9 – ident: 13088_CR27 doi: 10.1016/j.vaccine.2021.08.076 – volume: 13 start-page: 325 issue: 5 year: 2000 ident: 13088_CR41 publication-title: J Am Board Fam Pract – volume: 28 start-page: 4416 issue: 27 year: 2010 ident: 13088_CR37 publication-title: Vaccine doi: 10.1016/j.vaccine.2010.04.038 – volume: 9 start-page: e029087 issue: 7 year: 2019 ident: 13088_CR47 publication-title: BMJ Open. doi: 10.1136/bmjopen-2019-029087 – volume: 8 start-page: e191 issue: 2 year: 2020 ident: 13088_CR1 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(19)30482-6 – volume: 395 start-page: 575 issue: 10224 year: 2020 ident: 13088_CR56 publication-title: Lancet doi: 10.1016/S0140-6736(20)30068-4 – volume: 196 start-page: 445 issue: 7 year: 2012 ident: 13088_CR31 publication-title: Med J Aust doi: 10.5694/mja11.11360 – volume: 37 start-page: 272 issue: 2 year: 2019 ident: 13088_CR54 publication-title: Australia Vaccine doi: 10.1016/j.vaccine.2018.11.034 – ident: 13088_CR28 doi: 10.1007/978-1-4020-5614-7_2685 – volume: 17 start-page: 1085 issue: 12 year: 2018 ident: 13088_CR18 publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2018.1548282 – volume: 3 start-page: 611 issue: 5 year: 2017 ident: 13088_CR9 publication-title: J Glob Oncol doi: 10.1200/JGO.2016.008151 – volume: 4 start-page: e453 issue: 7 year: 2016 ident: 13088_CR2 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(16)30099-7 – volume: 139 start-page: 400 issue: 3 year: 2011 ident: 13088_CR32 publication-title: Epidemiol Infect doi: 10.1017/S095026881000066X – volume: 16 start-page: 600 year: 2016 ident: 13088_CR46 publication-title: BMC Public Health doi: 10.1186/s12889-016-3195-6 – volume: 68 start-page: 571 issue: 6 year: 2014 ident: 13088_CR34 publication-title: J Epidemiol Community Health doi: 10.1136/jech-2013-202629 – volume: 17 start-page: 7997 issue: 21 year: 2020 ident: 13088_CR60 publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph17217997 – ident: 13088_CR16 – volume: 211 start-page: 31 issue: 1 year: 2019 ident: 13088_CR48 publication-title: Med J Aust doi: 10.5694/mja2.50221 – volume: 346 start-page: f2032 year: 2013 ident: 13088_CR10 publication-title: Brit Med J. doi: 10.1136/bmj.f2032 – volume: 38 start-page: 91 issue: 1 year: 2014 ident: 13088_CR51 publication-title: Aust N Z J Public Health doi: 10.1111/1753-6405.12149 – volume: 7 start-page: e1000270 issue: 5 year: 2010 ident: 13088_CR23 publication-title: PLoS Med doi: 10.1371/journal.pmed.1000270 – volume: 14 start-page: 399 issue: 6 year: 2009 ident: 13088_CR17 publication-title: Eur J Contracept Reprod Health Care doi: 10.3109/13625180903229605 – volume: 122 start-page: 1560 issue: 10 year: 2016 ident: 13088_CR50 publication-title: Cancer doi: 10.1002/cncr.29954 – ident: 13088_CR26 – volume: 36 start-page: 36 issue: 1 year: 2014 ident: 13088_CR33 publication-title: J Public Health (Oxf) doi: 10.1093/pubmed/fdt042 – volume: 206 start-page: 204 issue: 5 year: 2017 ident: 13088_CR11 publication-title: Med J Aust doi: 10.5694/mja16.00597 – volume: 11 start-page: 227 year: 2013 ident: 13088_CR14 publication-title: BMC Med doi: 10.1186/1741-7015-11-227 – volume: 5 start-page: Cd009069 issue: 5 year: 2018 ident: 13088_CR12 publication-title: Cochrane Database Syst Rev – volume: 189 start-page: 12 issue: 1 year: 1999 ident: 13088_CR8 publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F – ident: 13088_CR43 – volume: 13 start-page: 607 issue: 6 year: 2012 ident: 13088_CR4 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70137-7 – volume: 16 start-page: 763 issue: 6 year: 2013 ident: 13088_CR6 publication-title: J Med Econ doi: 10.3111/13696998.2013.793691 – volume: 68 start-page: 57 issue: 1 year: 2014 ident: 13088_CR35 publication-title: J Epidemiol Commun Health doi: 10.1136/jech-2013-202620 |
SSID | ssj0017852 |
Score | 2.4267085 |
Snippet | Background
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,... In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable... Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,... In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable... Abstract Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 822 |
SubjectTerms | Adolescence Adolescent Adolescents Age Australia - epidemiology Biostatistics Cervical cancer Curricula Educational aspects Environmental Health Epidemiology Female Girls Health equity Health promotion HPV vaccines Human papillomavirus Humans Immunisation programs Immunization Male Medical screening Medicine Medicine & Public Health Methods Papillomavirus Infections - prevention & control Papillomavirus Vaccines Population Population statistics Primary prevention Public Health School-based Schools Special education Students Teenagers Vaccination Vaccine Vaccines Variation Warts |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_SkyCi1o_VKhEED7o0u_naPVaxPATFg5V6CvlaLJR9pbtP-uc7k-w-u5XWS6-bSTaZmWR-SWYmhLxxNewBQiVLUGBVChlFab2OJXMyNpx1ognJ2-KrWh2Jz8fy-NJTX-gTltMDZ8btixCUtVCrjVY46VwVQgCj20UeaxVT6B5r2byZmu4PdCPrOUSmUfsDrMLoGgQbL1izQTcuFmYoZev_d02-ZJSuOkxeuTVNxujwAbk_oUh6kHv_kNyJ_SNyLx_B0RxZtEt-fknnf9AAHVKuTXqKHkLUjvmVKwyaouhaTsc1HTZniMQnyhKNW6Crbz_ob-v9ST4ypJMz1_CYHB1--v5xVU4vKZReMT2WUWutmG8AGzRRVLpqtQPDHNqogKuN4DC02gbHdS24E07VTHot6yh9dKzt-BOy06_7-IxQjrmQ6pZ1nUXwESyzvOPKQSMgJK8LUs2MNX5KM46vXZyatN1olMnCMCAMk4RhLgryblvnLCfZuJH6A8prS4kJstMHUBszqY35n9oU5C1K2-A0hu55O0UjwCAxIZY50IiFW1jeCrK3oITp55fFs76YafoPBlCPSs7D8J_X22KsiS5tfVxvkEZKgJtAVZCnWb22Q-JSqAbYWxC9ULzFmJcl_cmvlBy8BUiSar6fVfRvt67n6fPb4OkLchfgpMS7tlrukZ3xfBNfAmQb3as0O_8A0Vc-VA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaqckFCiDehBRkJiQMEEj-TA0IFUa2QQBxYVE6WX4FKq2y7m0Xl3zPjJFtSSq_rcdbzsj_b4xlCnjkGe4BQyhwMWOVCRpFbr2NeOBkrXjSiCina4rOazcXHI3m0Q8ZyR4MA15du7bCe1Hy1eHV2-vstOPyb5PCVer2GORYDf2BbBTMyaB4w5bV0X4ShfOL8VkFXko0PZy7tN1mcUg7_f2fqv5aqi2GUF-5S0xJ1eIvcHLAlPeiN4TbZie0dcqM_mKP9e6O75PundCoIH6DrlIGTLjBuiNqur32FT6koBpzTbknXmxMUzUCZ45IX6OzLN_rLen_cHyTSIcRrfY_MDz98fT_Lh_oKuVeF7vKotVaFrwAxVFGUuqy1g-U61FFFKyrBgTVmg-OaCe6EU6yQXksWpY-uqBt-n-y2yzY-JJRjhiRWF01jEZIEW1jecOXgI6BwrzNSjoI1fkg-jjUwFiZtQiplemUYUIZJyjBnGXmx7XPSp964kvod6mtLiWmz0w_L1Q8zeKERIShrYUQ1MOikc2UIARBcE3lkKtYZeY7aNmhuMDxvhzcKwCSmyTIHGhFyDZNeRvYnlOCUfto82osZbdoAFlIppBj-5-m2GXtioFsblxukkRJAKFBl5EFvXluWuBSqAvFmRE8Mb8LztKU9_plShtcAVFLPl6OJng_r_zJ9dDUXe-Q6Q-cpRM7kPtntVpv4GCBa554kv_sD4mA3Zg priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEA6ygggiut6qq0QQfNBim2v7uB5cDsKKD66sTyG34sLSs9ge8ec7k-bU7XoB30ozSTOZmeRLMzMh5IVjsAcItSxBgVUpZBSl9TqWlZOx4VUnmpC8LT6o9Yl4fypPc5ocjIW5fH5fN-rNAPMnOvXAlglmW5Aq4MXrEh5Rm1dqNZ8Y6EayXVDMH-stFp6Un__3WfjSMnTVRfLKOWlafo7ukNsZN9LDSdB3ybXY75Mbx_lkfJ_cmv6_0Sms6B75cpx-_kFbdEiJNuk5ugdRO05XXGHEFEW_cjpu6LC9QBieKUtc2QJdf_xMv1sPzSfh0ezJNdwnJ0fvPq3WZb5GofSq0mMZtdaq8g0AgyaKWtetdrAqhzaqaEUjOHDJbHBcM8GdcIpV0mvJovTRVW3HH5C9ftPHR4RyTITE2qrrLCKPYCvLO64cNAJy9bog9W6Mjc85xvGqi3OT9hqNMpNcDMjFJLmYHwV5Nde5mDJs_JP6LYpupsTs2OkFKI3JxmZECMpa6FELDDrpXB1CAKDWRR6Zim1BXqLgDdowdM_bHIoATGI2LHOoEQi3MLcV5GBBCbbnl8U71THZ9gcDkEclz2H4zvO5GGuiP1sfN1ukkRKwJlAV5OGkaTNLXArVwPAWRC90cMHzsqQ_-5oyg7eAR1LN1ztt_dWtv4_p4_8jf0JuMrSrSpRMHpC98ds2PgVkNrpnySR_AqtRMIo priority: 102 providerName: Springer Nature |
Title | Measuring school level attributable risk to support school-based HPV vaccination programs |
URI | https://link.springer.com/article/10.1186/s12889-022-13088-x https://www.ncbi.nlm.nih.gov/pubmed/35468743 https://www.proquest.com/docview/2666667699 https://www.proquest.com/docview/2655560676 https://pubmed.ncbi.nlm.nih.gov/PMC9036743 https://doaj.org/article/4dd6aa30f9ea4b5bb1ddd727fe3e26e9 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9swULTpy2CMfddbFzQY7GEztWV9-WGMJDQLg4ZSlpHtRViWvBVKkjXJ6M_fnWync8f6Ikh0Mjrd6e50Ot0R8sYyOAO4VMTAwDLmwvO4KJWPEyu8zpKKaxeiLaZyMuOf52K-R6btWxgMq2xlYhDUblmij_wYFIkM8Zj5x9WvGKtG4e1qW0KjaEoruA8hxdg-OQCRLJIeORieTM_Od_cKSgvWPp3R8ngN0hlDhuBABrIceOa6o55CFv9_ZfVfyup2IOWt29SgpMYPyYPGuqSDmh0ekT2_eEzu1645Wr84ekK-nQa_IHyArkMOTnqJkUO02NTVr_AxFcWQc7pZ0vV2hRZ6Axmj0nN0cvaV_obFuKhdibQJ8lo_JbPxyZfRJG4qLMSlTNQm9kopmZQabAbtearSXFlQ2C730hdc8wxQY4WzmWI8s9xKlohSCeZF6W2SV9kz0lssF_6Q0AxzJLE8qaoCjRJXJEVWZdLCR4DkpYpI2i6sKZv041gF49KEY4iWpiaGAWKYQAxzHZF3uzGrOvnGndBDpNcOEhNnhz-WVz9Msw8Nd04WBcwoBwStsDZ1zoENV_nMM-nziLxFahvc3jC9smheKQCSmCjLDBTayDmIvYgcdSBhW5bd7pZfTCMW1uaGiSPyeteNIzHUbeGXW4QRAsxQgIrI85q9dihlgksNyxsR1WG8Ds7dnsXFz5A0PAdTJYx837LozbT-v6Yv7sbiJbnHcPMkPGbiiPQ2V1v_Coy0je2TfTVX0OpRiu34U7_Zi_BrJEf94PyA9pRraM-H36GdscEftHJB0Q |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFS2B5AQ4k2ggJFAHCBq1vEjOVSohVZb-lCFWtSeTBw7UKnaXbq7UH6Ob2PGSbakiN56jcdW7Hnb8wB4aTn6AK4vYyRgFQvpRVyU2seJlT5Lk0pkLkRb7KrBgfh4KA8X4HebC0Nhla1MDILajUq6I19GRaJCPGb-bvw9pq5R9LrattAomtYKbiWUGGsSO7b8r5_owk1WNj8gvl9xvrG-_34QN10G4lIlehp7rbVKygz1ZuZFX_dzbVFpudwrX4hMpN6VvHA21VykVljFE1lqyb0svU3yKsV1r8GioAuUHiyure_ufZq_Y-hM8jZVJ1PLE9QGFKKEDiDqDqTRs446DF0D_tUNfynHi4GbF15vg1LcuA23GmuWrdbkdwcW_PAu3KyvAlmd4XQPjnbCPSQuwCah5ic7oUglVkzrbluUvMUoxJ1NR2wyG5NH0EDGpGQdG-x9Zj_w8I_rq0vWBJVN7sPBlZz1A-gNR0P_CFhKNZl4nlRVQUaQK5IirVJlcREksVJH0G8P1pRNuXPqunFigtuTKVMjwyAyTECGOYvgzXzOuC72cSn0GuFrDkmFusOH0elX0_C9Ec6posA_ynGDVlrbd86hzVj51HPl8wheE7YNiRP8vbJosiJwk1SYy6xqsslzFLMRLHUgUQyU3eGWXkwjhibmnGkieDEfppkUWjf0oxnBSIlmL0JF8LAmr_mWkKZVhscbge4QXmfP3ZHh8bdQpDxH0yjMfNuS6Plv_f9MH1--i-dwfbC_s222N3e3nsANToyUiJjLJehNT2f-KRqIU_us4UIGX66a8f8APAJ2mg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELZQkSokhKAcDRQwEhIPEDXxmTwux2o5WvWBReXJsmMHkKrsqskifj4zTjY05ZB4XY-9Ho9n5nM8MybkqWNwBvC5TGEDq1TIIFJb6ZBmToaCZ7UofIy2OFaLpXh3Kk8vZPHHaPftlWSf04BVmprucO3rXsULddiCVcVQHzhIgQ0GWQOKvCrAV2NQ15LNxnsEXUi2TZX5Y7-JO4pV-3-3zRec0-XAyUu3p9EpzW-SGwOapLNe_LfIldDskd2j4b58j1zvv8rRPtnoNvl8FD8Jwli0jeU36RkGDVHb9Q9fYR4VxWhz2q1ou1kjOB8oU_R3ni5OPtHvtoLho0jpEN_V3iHL-ZuPrxbp8LhCWqlMd2nQWqusKgAuFEHkOi-1A1_ty6CCFYXgwCWz3nHNBHfCKZbJSksWZBVcVtb8LtlpVk3YJ5RjeSRWZnVtEY94m1lec-VgEJB2pROSb9fYVEPlcXwA48zEE0ihTC8XA3IxUS7mR0Kej33Wfd2Nf1K_RNGNlFgzO_6wOv9iBhU0wntlLcyoBAaddC733gN8qwMPTIUyIc9Q8AY1G6ZX2SFBAZjEGllmphEel2DxEnIwoQSNrKbN261jBovQGgBCKsYTw_88GZuxJ0a5NWG1QRopAYECVULu9TttZIlLoQpY3oToyR6c8Dxtab59jfXCS0ApseeL7W79Na2_r-n9_yN_THZPXs_Nh7fH7x-QawxVLBMpkwdkpzvfhIcA3Tr3KGrnT8QTO98 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Measuring+school+level+attributable+risk+to+support+school-based+HPV+vaccination+programs&rft.jtitle=BMC+public+health&rft.au=Vujovich-Dunn%2C+C&rft.au=Wand%2C+H&rft.au=Brotherton%2C+J+M+L&rft.au=Gidding%2C+H&rft.date=2022-04-25&rft.pub=BioMed+Central&rft.eissn=1471-2458&rft.volume=22&rft.spage=1&rft_id=info:doi/10.1186%2Fs12889-022-13088-x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |